- Author: Hugh Ringland Taylor, AC, MD, MBBS, BMedSc(Melb), DO(Melb), FRANZCO, FRACS, FAAO, FACS, FAICD; Chief Editor: Hampton Roy, Sr, MD more...
Further Outpatient Care
Long-term, intermittent follow-up care is required for patients with active or cicatricial disease.
One episode of infection may be treated adequately, but reinfection from the community pool of infection is likely unless an effective mass treatment campaign is implemented. When mass treatment is undertaken, antibiotic coverage should be as high as possible, with 80% being an absolute minimal target. It is important to treat all family members, especially the younger children.
Some studies suggest a great benefit if coverage in excess of 95% can be achieved.
Surgical patients require annual follow-up care because of the potential for recurrence.
Facial cleanliness and environmental improvement are major components of the SAFE strategy.
Many regard the lack of facial cleanliness in children as the key factor for the persistence of trachoma.
The prognosis depends on the severity of the disease at the time of treatment, the appropriateness of the treatment, and the risk of reinfection.
Patients in whom early disease is treated appropriately have an excellent prognosis.
Severe disease may be stabilized, but the patient's vision may not improve once corneal scarring has developed.
Reinfection worsens the prognosis.
Bobo LD, Novak N, Munoz B, Hsieh YH, Quinn TC, West S. Severe disease in children with trachoma is associated with persistent Chlamydia trachomatis infection. J Infect Dis. 1997 Dec. 176(6):1524-30. [Medline].
West SK, Munoz BE, Mkocha H, Gaydos C, Quinn T. Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control. Ophthalmic Epidemiol. 2015 Jun. 22 (3):170-5. [Medline].
Baker MC, Mathieu E, Fleming FM, et al. Mapping, monitoring, and surveillance of neglected tropical diseases: towards a policy framework. Lancet. 2010 Jan 16. 375(9710):231-8. [Medline].
Solomon AW, Pavluck AL, Courtright P, Aboe A, et al. The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study. Ophthalmic Epidemiol. 2015 Jun. 22 (3):214-25. [Medline].
Katibeh M, Hosseini S, Yaseri M, Aminifar MN, Mahdavi A, Jafarinasab MR, et al. Prevalence and Risk Factors for Trachoma in Rural Areas of Sistan-va-Baluchestan Province, Iran: A Population-Based Study. Ophthalmic Epidemiol. 2015 Jun. 22 (3):208-13. [Medline].
Ramyil A, Wade P, Ogoshi C, Goyol M, Adenuga O, Dami N, et al. Prevalence of Trachoma in Jigawa State, Northwestern Nigeria. Ophthalmic Epidemiol. 2015 Jun. 22 (3):184-9. [Medline].
Evans JR, Solomon AW. Antibiotics for trachoma. Cochrane Database Syst Rev. 2011 Mar 16. CD001860. [Medline].
West S, Munoz B, Lynch M, et al. Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet. 1995 Jan 21. 345(8943):155-8. [Medline].
Reacher M, Foster A, Huber J. Trichiasis surgery for trachoma: the bilamellar tarsal rotation procedure. WHO/PBL 93.29. Geneva: World Health Organization;. 1993.
Dawson CR, Schachter J, Sallam S, Sheta A, Rubinstein RA, Washton H. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis. 1997 Mar. 24(3):363-8. [Medline].
Grayston JT, Wang SP, Yeh LJ, Kuo CC. Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis. 1985 Nov-Dec. 7(6):717-25. [Medline].
Mabey DC, Solomon AW, Foster A. Trachoma. Lancet. 2003 Jul 19. 362(9379):223-9. [Medline].
Taylor HR, Johnson SL, Schachter J, Caldwell HD, Prendergast RA. Pathogenesis of trachoma: the stimulus for inflammation. J Immunol. 1987 May 1. 138(9):3023-7. [Medline].